G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2018

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2018

Summary

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - G protein-coupled bile acid receptor 1 (GPBAR1) is a protein encoded by the GPBAR1 gene. It is a receptor for bile acid. Bile acid-binding induces its internalization, activation of extracellular signal-regulated kinase and intracellular cAMP production. It is involved in the suppression of macrophage functions by bile acids.

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Dermatology and Gastrointestinal which include indications Type 2 Diabetes, Atopic Dermatitis, Diarrhea, Inflammatory Bowel Disease, Metabolic Syndrome, Non-Alcoholic Steatohepatitis (NASH), Obesity and Short Bowel Syndrome.

The latest report G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1)
- The report reviews G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Overview
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Companies Involved in Therapeutics Development
Ardelyx Inc
Cadila Healthcare Ltd
Intercept Pharmaceuticals Inc
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Drug Profiles
Drug to Agonize GPBAR1 for Type 2 Diabetes and Metabolic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-8940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0071261 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPBAR1 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TGR-5 Receptor for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TGR5 Receptor for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Dormant Products
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Discontinued Products
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Product Development Milestones
Featured News & Press Releases
Apr 18, 2017: Ardelyx To Present Poster on TGR5 agonist RDX8940 at Upcoming Spring Medical Meetings
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Ardelyx Inc, H2 2018
Pipeline by Cadila Healthcare Ltd, H2 2018
Pipeline by Intercept Pharmaceuticals Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Global Dental Gypsum Market Size study, by Product (Dental Plaster, Model Dental Stone, Die Dental Stone), by Application (Hospital, Clinic, Others) and Regional Forecasts 2018-2025

Global Dental Gypsum Market to reach USD 74.5 million by 2025.Global Dental Gypsum Market valued approximately USD 56 million in 2017 is anticipated to grow with a healthy growth rate

USD 3950 View Report

Global Organic Pharmaceutical Excipients Market Size study, by Product (Oleo Chemicals, Carbohydrates, Petrochemicals, Protein, Others), by Application (Oral Formulation, Topical Formulation, Parenteral Formulation, Others) and Regional Forecasts 2018-2025

Global Organic Pharmaceutical Excipients Market to reach USD XX million by 2025.Global Organic Pharmaceutical Excipients Market valued approximately USD XX million in 2017 is anticipated to grow with a healthy

USD 3950 View Report

2018 Global G-Protein Coupled Receptors (GPCRs) Industry Report - History, Present and Future

The global market size of G-Protein Coupled Receptors (GPCRs) is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by

USD 4000 View Report

Global Egg Protein Market Research Report 2018

Egg Protein Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the

USD 2850 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available